Publications by authors named "M B Effron"
Background: A previous single-center study of patients with myocardial infarction (MI) showed that platelet FcγRIIa (pFCG) can distinguish patients at higher and lower risk of subsequent MI, stroke, and death.
Objectives: The authors performed an 800-patient 25-center study to validate the prognostic implications of pFCG.
Methods: Patients with type 1 MI (ST-segment elevation and non-ST-segment elevation) were enrolled in a prospective noninterventional trial during their index hospitalization.
Article Synopsis
- The study aimed to assess the effectiveness and safety of low (81 mg) versus high-dose (325 mg) aspirin in patients with established atherosclerotic cardiovascular disease (ASCVD) across different racial groups.
- Conducted as a secondary analysis of the ADAPTABLE trial, the research involved over 14,000 participants from various racial backgrounds and compared their responses to different aspirin doses over a median follow-up of 26.2 months.
- The results indicated that race did not significantly alter the effectiveness or safety of aspirin dosing, suggesting that all racial groups responded similarly to the treatment.
Article Synopsis
- The study investigates how different data sources (like electronic health records, insurance claims, and participant reports) contribute to analyzing clinical outcomes in a pragmatic randomized clinical trial (RCT) involving patients with atherosclerotic cardiovascular disease.
- Conducted from April 2016 to June 2019, the ADAPTABLE study looked at the effects of daily aspirin doses on certain health events, while comparing participant data availability to enhance understanding of outcome rates.
- The findings revealed a predominance of participant-reported and EHR data, with only a small percentage relying solely on claims data, indicating the need for further study on the varying contributions of each data source to overall clinical results.
Article Synopsis
- - Atherosclerotic cardiovascular disease (ASCVD) is the main health issue in the US, and while aspirin is commonly used for its prevention, a trial (ADAPTABLE) found no significant difference in outcomes between 81 mg and 325 mg doses of aspirin.
- - The study aimed to investigate whether there are differences in safety and effectiveness of the two aspirin doses based on sex, as previous findings didn't address this.
- - Conducted across multiple medical centers, the ADAPTABLE trial involved over 15,000 participants with established ASCVD, analyzing outcomes related to major bleeding, heart attacks, and strokes, with a focus on comparing male and female responses to the aspirin doses.
Background: Reflecting clinical trial data showing improved outcomes with lower LDL-C levels, guidelines across the globe are increasingly recommending a goal of LDL-C <55 mg/dL in persons with atherosclerotic cardiovascular disease (ASCVD). What proportion of patients with ASCVD are already meeting those goals in the US remains understudied.
Methods: Using electronic health record data from 8 large US health systems, we evaluated lipid-lowering therapy (LLT), LDL-C levels, and factors associated with an LDL-C <55 mg/dL in persons with ASCVD treated between 1/1/2021-12/31/2021.